SAIF Partners IV L.P. Amends Sinovac Biotech Stake Filing

TL;DR

SAIF Partners IV L.P. updated their Sinovac Biotech filing on 6/17/24. Ownership details TBD.

AI Summary

SAIF Partners IV L.P. has amended its Schedule 13D filing regarding Sinovac Biotech Ltd. as of June 17, 2024. The filing indicates a change in the beneficial ownership of the company's common shares, though specific new ownership percentages or dollar amounts are not detailed in this excerpt. This amendment follows previous filings by SAIF Partners IV L.P. concerning their stake in Sinovac Biotech.

Why It Matters

Changes in major shareholder filings like this can signal shifts in control or investment strategy, potentially impacting the stock price and future corporate actions of Sinovac Biotech.

Risk Assessment

Risk Level: medium — Schedule 13D filings often involve significant investors, and changes can indicate strategic shifts or potential activism, carrying inherent market risk.

Key Players & Entities

• SAIF Partners IV L.P. (company) — Filing entity
• Sinovac Biotech Ltd. (company) — Subject company
• Andrew Y. Yan (person) — Contact person for filing

FAQ

Key Financial Figures

• $0.001 — elating to the common shares, par value $0.001 per share (the “Common Shares&rdq

Filing Documents

• tm2417413d1_sc13da.htm (SC 13D/A) — 61KB
• tm2417413d1_ex7-07.htm (EX-7.07) — 18KB
• 0001104659-24-072251.txt ( ) — 81KB

Contracts, Arrangements, Understandings or Relationships

Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

is hereby amended and supplemented as follows

Item 6 is hereby amended and supplemented as follows: On June 13, 2024, the Seller and the Buyer entered into an amendment No.5 to the Investment Agreement (the “Amendment No.5”) to extend the period of the Buyer’s right of first refusal period (“ROFR Period”), during which the Buyer has a right to elect to purchase all of the shares of the Issuer that the Seller would sell to any person (other than any of its affiliate or an existing limited partner) at the same price and subject to the same material terms and conditions proposed by such person under the Investment Agreement (as amended), to August 25, 2024. As a result of this extension of the ROFR Period, the period during which the Buyer may exercise the Put Option is also extended in the following manner: (i) if the Buyer and the Seller enter into a share purchase agreement with respect to any shares of the Issuer by August 25, 2024, the Seller may exercise the Put Option prior to the closing of the sales under such share purchase agreement to sell the Put Option Shares to the Buyer; and (ii) if no such share purchase agreement is executed by August 25, 2024, the Seller may exercise the Put Option within 15 business days immediately after August 25, 2024 to sell the Put Option Shares to the Buyer. References to each of the Investment Agreement and the Amendment No.5 in this Statement are qualified in their entirety by reference to the Investment Agreement and the Amendment No.5, which are attached hereto as exhibits or incorporated herein by reference as if set forth in their entirety herein.

Material to Be Filed as Exhibits

Item 7. Material to Be Filed as Exhibits.

of the Original Schedule 13D is hereby amended and restated

Item 7 of the Original Schedule 13D is hereby amended and restated as follows: Exhibit 7.01 Joint Filing Agreement by and among SAIF Partners IV L.P., SAIF IV GP L.P. and SAIF IV GP Capital Ltd., dated as of June 27, 2017. Exhibit 7.02 Investment Agreement dated November 1, 2022 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.03 Amendment No.1 to Investment Agreement dated March 15, 2023 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.04 Amendment No.2 to Investment Agreement dated May 25, 2023 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.05 Amendment No.3 to Investment Agreement dated September 15, 2023 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.06 Amendment No.4 to Investment Agreement dated December 1, 2023 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.07 Amendment No.5 to Investment Agreement dated June 13, 2024 between SAIF Partner IV L.P. and YZ Healthcare L.P. CUSIP No. P8696W104 Page 6 of 6 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: June 17, 2024 SAIF Partners IV L.P. By: /s/ Andrew Y. Yan Name: Andrew Y. Yan Title: Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P., which is the General Partner of SAIF Partners IV L.P. SAIF IV GP L.P. By: /s/ Andrew Y. Yan Name: Andrew Y. Yan Title: Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P. SAIF IV GP Capital Ltd. By: /s/ Andrew Y. Yan Name: Andrew Y. Yan Title: Director of SAIF IV GP Capital Ltd.